Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT-210 in active ulcerative colitis
CTR20260703Phase 2Active
- Sponsor
- Yikun Xingjian
- Start
- Jun 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of INT-210 in autoimmune colitis, sponsored by Yikun Xingjian. Started Jun 2026; status: active.
02
Drugs
INT-210
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20260703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260703.